Site selection with biospatial’s platform

The biospatial platform can be used to identify top sites and geographic regions in near real-time.

biospatial’s vice president of growth Andrew Schafer sat down with the CEO of InterveXion Therapeutics and Applied Clinical Trials to discuss how biospatial’s platform was used to bolster site selection efforts for a Phase 2 methamphetamine overdose study.

The discussion covers how biospatial, Syneos Health, and InterveXion Therapeutics formed a partnership for this study, how EMS data accessible through the biospatial platform can be used to refine site selection efforts, and how electronic Patient Care Report (ePCR) data was used for patient recruitment.

To learn more about biospatial’s partnership with Syneos Health and InterveXion Therapeutics, read our press release on the subject here.

Find out more about the Phase II Meth-OD study here.